Hepatomegaly (HP:0002240)
Abnormally increased size of the liver.
Synonyms: Enlarged liver
Cross References: MSH:D006529, SNOMEDCT_US:80515008, UMLS:C0019209
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Primary immunodeficiency | 5.941e-18 | 2.198e-16 | 1502.29 | 59587.92 |
| 2 | T cell receptor signaling pathway | 8.515e-10 | 1.575e-8 | 200.92 | 4196.00 |
| 3 | Th1 and Th2 cell differentiation | 8.619e-8 | 0.000001063 | 150.77 | 2452.58 |
| 4 | Autoimmune thyroid disease | 0.000002081 | 0.00001283 | 170.91 | 2236.02 |
| 5 | Hematopoietic cell lineage | 1.159e-7 | 0.000001072 | 139.61 | 2229.69 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | positive thymic T cell selection (GO:0045059) | 8.995e-10 | 1.151e-7 | 4283.14 | 89214.48 |
| 2 | V(D)J recombination (GO:0033151) | 0.00001235 | 0.0001580 | 555.03 | 6273.06 |
| 3 | T cell differentiation in thymus (GO:0033077) | 0.00002041 | 0.0002375 | 416.21 | 4494.85 |
| 4 | B cell activation involved in immune response (GO:0002312) | 0.00002690 | 0.0002869 | 356.71 | 3753.85 |
| 5 | regulation of T cell differentiation (GO:0045580) | 8.148e-7 | 0.00002027 | 237.55 | 3330.49 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | endodeoxyribonuclease activity (GO:0004520) | 0.009957 | 0.06558 | 116.79 | 538.34 |
| 2 | phosphatidylinositol-3,5-bisphosphate binding (GO:0080025) | 0.01194 | 0.06558 | 96.46 | 427.12 |
| 3 | wide pore channel activity (GO:0022829) | 0.01243 | 0.06558 | 92.44 | 405.55 |
| 4 | phosphatidylinositol-3,4-bisphosphate binding (GO:0043325) | 0.01293 | 0.06558 | 88.73 | 385.85 |
| 5 | tumor necrosis factor receptor superfamily binding (GO:0032813) | 0.01392 | 0.06558 | 82.15 | 351.18 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | T cell receptor complex (GO:0042101) | 1.975e-8 | 2.765e-7 | 951.48 | 16879.14 |
| 2 | alpha-beta T cell receptor complex (GO:0042105) | 0.000003371 | 0.00002360 | 1249.13 | 15739.23 |
| 3 | cytolytic granule (GO:0044194) | 0.003495 | 0.009787 | 370.07 | 2093.27 |
| 4 | clathrin-coated endocytic vesicle (GO:0045334) | 0.0007857 | 0.002750 | 59.96 | 428.66 |
| 5 | clathrin-coated endocytic vesicle membrane (GO:0030669) | 0.03398 | 0.07719 | 32.55 | 110.09 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| CTLA4 | IPILIMUMAB, ABATACEPT |
| CD40LG | – |
| CD3E | MUROMMONAB-CD3, CATUMAXOMAB, BLINATUMOMAB |
| PRF1 | EMAPALUMAB |
| ZAP70 | – |
| CD3D | MUROMMONAB-CD3, CATUMAXOMAB, BLINATUMOMAB |
| CD19 | BLINATUMOMAB |
| IL2RA | BASILIXIMAB, DACLIZUMAB, ALDESLEUKIN, DENILEUKIN DIFTITOX, CETIRIZINE |
| RAG1 | – |
| RAG2 | – |
